Business
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
- Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global
About this update from Amylyx Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Dr. Bedrosian brings to Amylyx nearly 30 years of leadership in clinical research, development, and advancing pipeline programs into commercialized global products including as CMO at Ultragenyx, Alexion, and ARIAD Pharmaceuticals\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAmylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the appointment of Camille L. Bedrosian, MD, as Chief Medical Officer (“CMO”). In this role, Dr. Bedrosian will lead global functions in medical affairs, regulatory, safety and pharmacovigilance, biometrics, clinical development, and clinical operations. Dr. Bedrosian brings nearly 30 years of experience addressing unmet medical needs for people with rare and serious diseases through successful clinical and translational research programs, including as CMO at Ultragenyx Pharmaceutical Inc. (“Ultragenyx”), Alexion Pharmaceuticals, Inc. (“Alexion”), and ARIAD Pharmaceuticals Inc. (“ARIAD”). Amylyx’ current CMO, Patrick Yeramian, MD, MBA, will stay on as an advisor through the end of the year and will then transition into retirement, as announced in December 2022.\n\n\n“We are thrilled to have Dr. Bedrosian join us on our mission to end the suffering caused by neurodegenerative diseases and to help usher in a new era of innovation for the communities we are serving,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “Dr. Bedrosian brings extensive experience having developed multiple successful medicines and facilitated global access to them, and her experience will be invaluable at Amylyx as we advance on our mission.”\n\n\nPrior to joining Amylyx, Dr. Bedrosian served most of her nearly six years at Ultragenyx as the Executive Vice President and CMO where she was responsible for leading drug development programs and supporting translational research programs. During her time, she helped Ultragenyx grow and greatly advance its many pipeline programs in rare genetic diseases to their current and exciting pivotal stages. While CMO for Alexion, she led the development of drugs and drug candidates, including those designed to address devastating rare diseases caused by defects in the complement system for people with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Prior to Alexion, Dr. Bedrosian was CMO for ARIAD, where she led drug development...